Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.

Published on Jun 12, 2020in Journal of Chemotherapy1.714
路 DOI :10.1080/1120009X.2020.1775424
Periklis Panagopoulos16
Estimated H-index: 16
(DUTH: Democritus University of Thrace),
Vasilis Petrakis3
Estimated H-index: 3
(DUTH: Democritus University of Thrace)
+ 4 AuthorsDimitrios Papazoglou22
Estimated H-index: 22
(DUTH: Democritus University of Thrace)
Sources
Abstract
Corona Virus Disease (CoVID-19) is an emerging public health problem rapidly spread globally. New treatment options for patients with severe symptoms and ways of reducing transmission in the community are taken into consideration. A retrospective study was conducted in the Department of Infectious Diseases of Alexandroupolis (Greece) including 16 patients with CoVID-19. They were classified into two groups, A and B. Group A received lopinavir/ritonavir as a third agent in the antiviral regimen, while group B did not. Lymphocytes were more significantly increased in patients of group A. Ferritin serum levels were also decreased significantly in these patients. Number of days needed for a first negative result of Real Time- Polymerase Chain Reaction (RT-PCR) was lower for Group A. The present study suggests that lopinavir/ritonavir may reduce the viral carriage in a shorter period of time compared with other antiviral regimens. Further studies are needed in order to evaluate the effectiveness of lopinavir/ritonavir in the treatment of patients with SARS-CoV-2 infection.
Download
馃摉 Papers frequently viewed together
11 Authors (G. Peytavin)
20201.06medRxiv
24 Authors (Fang Zheng, ..., Guozhong Gong)
References11
Newest
#1Bin Cao (China-Japan Friendship Hospital)H-Index: 58
#4Wen Liu (Wuhan Jinyintan Hospital)H-Index: 1
Abstract Background No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open-label trial involvin...
Source
#1Yan Rong GuoH-Index: 1
#2Qing Dong Cao (SYSU: Sun Yat-sen University)H-Index: 1
Last. Yan Yan (SYSU: Sun Yat-sen University)H-Index: 7
view all 9 authors...
An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome cor...
Source
#1Zhenwei Wang (SHU: Shanghai University)H-Index: 1
#2Xiaorong ChenH-Index: 2
Last. Wei Zhang (SHU: Shanghai University)H-Index: 1
view all 5 authors...
Pneumonia associated with the 2019 novel coronavirus (2019-nCoV) is continuouslyand rapidly circulating at present. No effective antiviral treatment has beenverified thus far. We report here the clinical characteristics and therapeuticprocedure for four patients with mild or severe 2019-nCoV pneumonia admitted toShanghai Public Health Clinical Center. All the patients were given antiviraltreatment including lopinavir/ritonavir (Kaletra((R))), arbidol, and ShufengJiedu Capsule (SFJDC, a tradition...
Source
#1Chih-Cheng LaiH-Index: 34
#2Tzu Ping ShihH-Index: 1
Last. Po-Ren Hsueh (NTU: National Taiwan University)H-Index: 111
view all 5 authors...
ABSTRACT Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019, has caused a large global outbreak and a major public health issue. As of February 11, 2020, data from the WHO has shown that more than 43,000 confirmed cases have been identified in 28 countries/regions, with more than 99% of the cases being detected in China. On January 30, 2020, WHO has declared C...
Source
#1Manli Wang (CAS: Chinese Academy of Sciences)H-Index: 17
#2Ruiyuan CaoH-Index: 7
Last. Gengfu Xiao (CAS: Chinese Academy of Sciences)H-Index: 32
view all 10 authors...
Source
#1Hongzhou Lu (Fudan University)H-Index: 33
As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus(2019-nCoV) have been reported in 25 provinces (districts and cities) in China.At present, there is no vaccine or antiviral treatment for human and animalcoronavirus, so that identifying the drug treatment options as soon as possibleis critical for the response to the 2019-nCoV outbreak. Three general methods,which include existing broad-spectrum antiviral drugs using standard assays,screening of a chemical library containin...
Source
#1Na Zhu (CCDC: Chinese Center for Disease Control and Prevention)H-Index: 11
#2Dingyu Zhang (CDC: Centers for Disease Control and Prevention)H-Index: 1
Last. Wenjie TanH-Index: 31
view all 18 authors...
Summary In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through...
Source
#1Yaseen M. Arabi (National Guard Health Affairs)H-Index: 82
#2Ayed Y. AsiriH-Index: 2
Last. Majed Al Jeraisy (National Guard Health Affairs)H-Index: 4
view all 33 authors...
Abstract The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-尾1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-尾1b provided with standard supportive care, compared to placebo provided with standard supportive care, in hospitalized patients with laboratory-confirmed MERS. The MIRACLE trial is designed as a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind ...
Source
ABSTRACT The efficacy and safety of a combination regimen including either efavirenz or lopinavir鈥搑itonavir was examined in a cohort of 65 patients positive for human immunodeficiency virus-1 (HIV-1). Both the efavirenz ( n = 33, 18 anti-retroviral naive) and lopinavir鈥搑itonavir ( n = 32, 15 naive) regimens achieved significant changes from baseline CD4 cell counts and HIV RNA levels after 108 weeks (p 10 , interquartile range (IQR) 2.2鈥3.8 log 10 vs. 2.4 log 10 , IQR 0.9鈥3.3 log 10 , respective...
Source
#1Chung-Ming Chu (United Christian Hospital)H-Index: 30
#2V C C ChengH-Index: 1
Last. Kwok-Yung YuenH-Index: 159
view all 12 authors...
Background: The clinical response of patients with severe acute respiratory syndrome (SARS) to a combination of lopinavir/ritonavir and ribavirin was examined after establishing the in vitro antiviral susceptibility of the SARS associated coronavirus to a panel of antiviral agents. Methods: The in vitro susceptibility of the prototype of SARS associated coronavirus to a panel of nucleoside analogues and protease inhibitors currently licensed for clinical use was studied. Forty one patients with ...
Source
Cited By10
Newest
Source
#1Eduarda Luiza Maciel da Silva (Universidade Federal da Fronteira Sul)H-Index: 1
#2Guilherme Vin铆cio de Sousa Silva (Universidade Federal da Fronteira Sul)H-Index: 2
Last. Cesar Andres Diaz AriasH-Index: 1
view all 4 authors...
A pandemia causada pelo novo coronavirus (SAR-CoV-2) representa um desafio para a saude publica do mundo inteiro, em funcao da alta transmissibilidade do virus, consequente sobrecarga dos sistemas de saude e grande numero de obitos. Assim, estudos e pesquisas estao sendo realizados no intuito de identificar alternativas terapeuticas seguras e eficazes para a COVID-19, doenca causada pelo SAR-CoV-2, visto que ainda nao ha um consenso nem evidencia cientifica de que algum medicamento possa suprimi...
Source
Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with COVID-19 to assess the efficacy of LPV/r for the treatment of Cornonavirus disease 19 (COVID-19). Methods: The authors systematically searched PubMed and MedRxiv databases for studies describing treatment of COVID-19 patients using LPV/r compared to other therapies. Articles were excluded if they were case reports, opinion editorials, preclinical studie...
Source
#1Seri Jo (Ewha Womans University)H-Index: 5
#2Suwon Kim (Ewha Womans University)H-Index: 6
Last. Dong Hae Shin (Ewha Womans University)H-Index: 15
view all 5 authors...
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), results in serious chaos all over the world. In addition to the available vaccines, the development of treatments to cure COVID-19 should be done quickly. One of the fastest strategies is to use a drug-repurposing approach. To provide COVID-19 patients with useful information about medicines currently being used in clinical trials, twenty-four compounds, including antivira...
Source
#1Pan LuoH-Index: 4
#2Jian-Ling ZhengH-Index: 2
Last. Juan LiH-Index: 5
view all 8 authors...
ABSTRACT Aim The inconsistent effects of lopinavir鈥搑itonavir (LPV/r) on COVID-19 seem to be caused by the therapeutic window. In the present study, we aim to present the effects of early LPV/r treatment on patients with severe COVID-19. Methods The demographics, characteristics, treatments, SARS-CoV-2 test results and outcomes of 19 patients with severe COVID-19 treated with LPV/r within 12 days of onset of symptoms were retrospectively assessed. Results Within 3 days of admission, three (15.79%...
Source
Background null Following the outbreak of the COVID-19 pandemic, there was a surge of research activity to find methods/drugs to treat it. There has been drug-repurposing research focusing on traditional medicines. Concomitantly, many researchers tried to find in silico evidence for traditional medicines. There is a great increase in article publication to commensurate the new-found research interests. This situation inspired the authors to have a comprehensive understanding of the multitude of ...
Source
#1Shusuke Mori (Tokyo Medical and Dental University)H-Index: 5
#2Tomohiko Ai (Tokyo Medical and Dental University)H-Index: 21
Last. Yasuhiro Otomo (Tokyo Medical and Dental University)H-Index: 18
view all 3 authors...
The impact of the COVID-19 pandemic has been immense, while the epidemiology and pathophysiology remain unclear. Despite many casualties in many countries, there have been less than 1,000 deaths in Japan as of end of June, 2020. In this study, we analyzed the cases of COVID-19 patients admitted to our institution located in the Tokyo metropolitan area where the survival rate is higher than those in other cities in the world. Medical records of COVID-19 patients that were admitted to a single Jap...
Source
#1Luana Heimfarth (Yahoo!)H-Index: 1
#2Mairim Russo Serafini (UFS: Universidade Federal de Sergipe)H-Index: 25
Last. Lucindo J. Quintans-J煤nior (UFS: Universidade Federal de Sergipe)H-Index: 43
view all 5 authors...
Abstract Coronavirus disease 2019 (COVID-19), the infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an aggressive disease that attacks the respiratory tract and has a higher fatality rate than seasonal influenza. The COVID鈥19 pandemic is a global health crisis, and no specific therapy or drug has been formally recommended for use against SARS-CoV-2 infection. In this context, it is a rational strategy to investigate the repurposing of existing drug...
Source
#1Siew Li Teoh (Monash University Malaysia Campus)H-Index: 7
#2Yi H. Lim (Taylors University)H-Index: 1
Last. Shaun Wen Huey Lee (Monash University Malaysia Campus)H-Index: 25
view all 4 authors...
The outbreak of a novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 has now become a pandemic with no approved therapeutic agent. At the moment, the genomic structure, characteristics and pathogenic mechanisms of SARS-CoV-2 have been reported. Based upon this information, several drugs including the directly acting antivirals have been proposed to treat people with coronavirus disease 2019 (COVID-19). This rapid review aims to describe the directly acting antivirals that have been ...
Source
#1Olga TarasovaH-Index: 10
#2Sergey IvanovH-Index: 9
Last. Vladimir PoroikovH-Index: 41
view all 4 authors...
Viruses can be spread from one person to another; therefore, they may cause disorders in many people, sometimes leading to epidemics and even pandemics. New, previously unstudied viruses and some specific mutant or recombinant variants of known viruses constantly appear. An example is a variant of coronaviruses (CoV) causing severe acute respiratory syndrome (SARS), named SARS-CoV-2. Some antiviral drugs, such as remdesivir as well as antiretroviral drugs including darunavir, lopinavir, and rito...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.